Activating mutations in IL-7Rα have been identified in approximately 10% of T-ALL patients, most frequently leading to the introduction of a cysteine residue which allows ligand-independent homodimerization of the receptor and consequent constitutive signaling [126,127]. This evidence concerns the gene IL7R and acute lymphoblastic leukemia.